Company news

Compass Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

April 15, 2024

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

April 11, 2024

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

April 9, 2024

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 8, 2024

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

March 20, 2024

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

February 28, 2024

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

February 27, 2024

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 2, 2023

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

June 21, 2023

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

May 3, 2023

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 25, 2023

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

March 27, 2023

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 14, 2023

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

February 1, 2023

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

January 18, 2023

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

January 5, 2023

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

December 14, 2022

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

November 30, 2022

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

November 21, 2022

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 8, 2022

Compass Therapeutics to Present at Upcoming Investment Conferences

November 7, 2022

Compass Therapeutics Announces $80 Million Private Placement

November 1, 2022

Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)

October 10, 2022

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

September 8, 2022

Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

August 1, 2022

Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 31, 2022

Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

May 30, 2022

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

May 22, 2022

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 8, 2022

Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11: 20 a.m. PT

May 4, 2022

Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

May 3, 2022

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

May 2, 2022

Compass Therapeutics Announces Appointment of Two New Directors to its Board

April 25, 2022

Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

April 7, 2022

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

March 29, 2022

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 20, 2022

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

January 19, 2022

Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 21, 2021

Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 11, 2021

Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

October 31, 2021

Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

October 31, 2021

Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle

October 31, 2021

CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 7, 2021

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 30, 2021

Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference

August 12, 2021

Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.

May 12, 2021

Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

March 4, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 8 decks. Every deck is listed under its year.